Pulmatrix to Merge with Cullgen to Form Nasdaq-Listed Company Focused on Targeted Protein Degradation
November 13, 2024
Pulmatrix announced a proposed merger with Cullgen to create a Nasdaq-listed biopharmaceutical company focused on targeted protein degradation, including three degrader programs in or about to begin Phase 1 clinical trials. The combined company is expected to operate as Cullgen Inc. headquartered in San Diego, California, with closing expected by end of March 2025 subject to approvals. As part of the merger agreement, Pulmatrix plans to divest certain assets, and Pulmatrix stockholders are expected to receive a special cash dividend contingent on net cash at closing.
- Buyers
- Cullgen Inc.
- Targets
- Pulmatrix, Inc., Cullgen Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Gyre Therapeutics to Acquire Cullgen in All-Stock Deal
March 2, 2026
Healthcare Services
Gyre Therapeutics entered into a definitive agreement to acquire Cullgen Inc. in an all-stock transaction valued at approximately $300 million. The acquisition is expected to close in early Q2 2026 and create a fully integrated biopharmaceutical company with a targeted protein degradation (TPD/DAC) platform and pipeline.
-
Pulmatrix Acquires Eos SENOLYTIX in Definitive Merger to Advance Mitochondrial Therapies
March 26, 2026
Biotechnology
Pulmatrix and Eos SENOLYTIX announced a definitive merger agreement under which Pulmatrix will acquire Eos. The combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker EOSX, with the deal funded alongside $19 million of concurrent private financings to advance Eos’s MitoXcel platform and lead candidate PTC-2105 for sarcopenia and sarcopenic obesity.
-
Genexine Announces Merger with EPD Biotherapeutics (EPD Bio)
July 4, 2024
Biotechnology
Genexine, a clinical-stage Korean biopharmaceutical company, announced a small-scale merger with EPD Biotherapeutics (EPD Bio) to strengthen its drug development pipeline. The merger is intended to add PROTAC/bioPROTAC (bioPROTAC via EPDegTM mRNA-LNP) technology talent and expand Genexine’s R&D capabilities, with EPD Bio’s founder joining Genexine to lead R&D.
-
Genmab A/S Acquires Merus N.V. via Tender Offer
December 12, 2025
Biotechnology
Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.
-
Cyclerion Therapeutics to Merge With Korsana Biosciences in All-Stock Deal
April 1, 2026
Healthcare Services
Cyclerion Therapeutics and Korsana Biosciences have entered into a definitive merger agreement in an all-stock transaction, with the combined company to operate under the Korsana Biosciences name and trade on Nasdaq as KRSA. The merger is supported by an oversubscribed private financing expected to generate approximately $380 million in gross proceeds to fund Korsana operations into 2029.
-
AbCellera Acquires TetraGenetics
September 13, 2021
Biotechnology
AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.